325 related articles for article (PubMed ID: 29464828)
1. Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer.
Matsutani S; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Hirakawa K; Ohira M
Cancer Sci; 2018 Apr; 109(4):966-979. PubMed ID: 29464828
[TBL] [Abstract][Full Text] [Related]
2. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
4. [Changes in the CD8+ Density of Tumor Infiltrating Lymphocytes after Neoadjuvant Radiochemotherapy in Patients with Rectal Adenocarcinom].
Buka D; Dvořák J; Sitorová V; Hátlová J; Richter I; Sirák I
Klin Onkol; 2016; 29(3):204-9. PubMed ID: 27296405
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy.
Miyakita H; Sadahiro S; Suzuki T; Chan LF; Ogimi T; Okada K; Yamamoto S; Kajiwara H
Oncology; 2020; 98(12):869-875. PubMed ID: 32799200
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
[TBL] [Abstract][Full Text] [Related]
7. Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer.
Huang Y; Lou XY; Zhu YX; Wang YC; Zhang L; Liu HL; Wang C; Zhan HM; Cheng ZQ; Tan WY; Wang L; Fan XJ
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30867256
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?
Schollbach J; Kircher S; Wiegering A; Seyfried F; Klein I; Rosenwald A; Germer CT; Löb S
Cancer Immunol Immunother; 2019 Apr; 68(4):563-575. PubMed ID: 30671614
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
10. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response.
McCoy MJ; Hemmings C; Anyaegbu CC; Austin SJ; Lee-Pullen TF; Miller TJ; Bulsara MK; Zeps N; Nowak AK; Lake RA; Platell CF
Oncotarget; 2017 Mar; 8(12):19803-19813. PubMed ID: 28177891
[TBL] [Abstract][Full Text] [Related]
11. Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer.
Teng F; Mu D; Meng X; Kong L; Zhu H; Liu S; Zhang J; Yu J
Am J Cancer Res; 2015; 5(6):2064-74. PubMed ID: 26269765
[TBL] [Abstract][Full Text] [Related]
12. The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type.
Miskad UA; Rifai RA; Masadah R; Nelwan B; Ahmad D; Cangara H; Prihantono P; Zainuddin AA; Rahawarin H
Breast Dis; 2021; 40(S1):S9-S14. PubMed ID: 34092582
[TBL] [Abstract][Full Text] [Related]
13. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
[TBL] [Abstract][Full Text] [Related]
14. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of CD45RO(+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy.
Wang L; Zhai ZW; Ji DB; Li ZW; Gu J
Int J Colorectal Dis; 2015 Jun; 30(6):753-60. PubMed ID: 25935450
[TBL] [Abstract][Full Text] [Related]
16. The local immune phenotype influences prognosis in patients with nodal-positive rectal cancer after neoadjuvant chemoradiation.
Schollbach J; Kircher S; Wiegering A; Anger F; Rosenwald A; Germer CT; Löb S
Int J Colorectal Dis; 2020 Feb; 35(2):365-370. PubMed ID: 31828368
[TBL] [Abstract][Full Text] [Related]
17. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
18. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
[TBL] [Abstract][Full Text] [Related]
19. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer.
Shinto E; Omata J; Sikina A; Sekizawa A; Kajiwara Y; Hayashi K; Hashiguchi Y; Hase K; Ueno H
BJS Open; 2020 Apr; 4(2):301-309. PubMed ID: 32026629
[TBL] [Abstract][Full Text] [Related]
20. Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy.
Huang CY; Chiang SF; Ke TW; Chen TW; Lan YC; You YS; Shiau AC; Chen WT; Chao KSC
Cancer Immunol Immunother; 2018 Apr; 67(4):551-562. PubMed ID: 29270668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
